Anglo-Swedish group AstraZeneca got a jolt when it stopped the experimentation of the diabetes drug ‘Galida’. Because of this setback, its shares touched new low. Galida was in the phase III experimental trials. It was one of the biggest new drug hopes with an expected prospective sales of $800m.



The company said that levels of creatinine, a waste product found in the blood, which can indicate kidney problems, were much higher than expected in patients taking Galida.



The decision to drop Galida was followed by long-standing concerns. The failure of another late-stage drug highlighted AstraZeneca’s need to restructure its developmental process.



Read